- Rhinomed (RNO) receives an order for one million Rhinoswabs from the Victorian Health Department to support the state’s COVID-19 testing
- The technology aims to make the collection of nasal swabs easier and more comfortable, thereby accelerating the process and reducing waiting times
- Additionally, Rhinoswab distributors have been appointed in Western Australia and Europe
- Shares are trading 16 per cent up at 43.5 cents each at 11:57 am AEST
Rhinomed (RNO) has received a purchase order for one million Rhinoswabs from the Victorian Government to support the state’s COVID-19 testing capability.
RNO develops wearable nasal and respiratory technologies and said it designed Rhinoswab to make the sample collection process easier.
To this end, the product is reportedly more comfortable and easier to use than a standard nasal swab. It is therefore able to capture a larger sample, accelerating the process and reducing waiting times.
The latest purchase by Victoria’s Department of Health follows an order for one million Rhinoswabs received from New South Wales’ Government last month.
Rhinomed CEO Michael Johnson said the company was pleased to receive further validation of its product.
“The Rhinoswab can make a meaningful impact on the SARS-CoV-2 testing process and enable more people to be tested quickly and easily,” he said.
“With well over two billion SARS- CoV-2 tests having been carried out globally over the past 18 months —and close to 26 million in Australia alone — there is a major opportunity for Rhinoswab to radically improve the testing process, clinical outcomes and user experience.”
Meanwhile, the company is continuing to scale up its manufacturing capabilities to accomodate growing domestic and international demand for its technology.
At present, Rhinoswab is registered with the United States’ Food and Drug Administration (FDA) and has a European CE mark, with further developments underway for its sales pipeline.
In other news, Rhinomed has appointed AntiMicrobial Technologies Group as a distributor of Rhinoswab in Western Australia and BioTrading Benelux BV as a distibutor in Belgium, the Netherlands and Luxembourg.
On Friday, shares were trading 16 per cent up at 43.5 cents each at 11:57 am AEST.